7 Oncologists and Cancer Centers in India Combining Standard Chemotherapy with Experimental Immunotherapy Protocols in 2026
A midnight text from a relative lands with a link to a study: chemotherapy plus immunotherapy cut recurrence in half for a specific colon cancer subtype. Your own oncologist never brought it up.
That gap between what shows up in a medical journal and what gets mentioned in a fifteen-minute consultation is where the anxiety creeps in. Immune checkpoint inhibitors paired with standard chemotherapy are already changing outcomes, but only for specific, biomarker-defined groups of patients, not everyone with a cancer diagnosis.
Getting access means finding the right biomarker test, the right trial or protocol, and a team equipped to manage the toxicity that comes with reactivating the immune system.
This guide profiles seven real options in India, ranging from an individual oncologist's private practice to some of the country's largest cancer institutes, so you know where to start looking.
Key Takeaways
Combining chemotherapy with experimental immunotherapy means adding an investigational immune-activating drug to a proven chemo backbone, inside a trial or a closely monitored protocol, not simply stacking on an extra medicine.
The benefit is real but conditional. A 50% cut in recurrence for dMMR colon cancer, sharply higher response rates in ImPrint-positive breast cancer, and improved one-year survival at ultra-low nivolumab doses for head and neck cancer are each tied to a specific biomarker or protocol, not a blanket guarantee.
India already has working access points for this combination, from Dr Bharat Patodiya's Pi Cancer Care's integrated setup in Hyderabad to Tata Memorial Hospital's trial pipeline, each suited to a different budget, biomarker result, and comfort level with paperwork.
Toxicity is the other half of the equation. The same regimens that push response rates up also cause real endocrine and organ complications, which is why a monitoring team matters as much as the drug itself.
Chemo-Immunotherapy Centers in India, Compare
Institution | Type | Core Strength | Best For | City |
Dr. Bharat Patodiya's Pi Cancer Care | Private hospital | Integrated oncology care under an immunotherapy-certified oncologist | Patients wanting one facility across diagnostics, chemo, and biologic treatment | Hyderabad |
Tata Memorial Hospital | Government trial site | Largest registered trial volume in India | Patients seeking audited, protocol-based trial access | Mumbai |
HCG Cancer Centre | Private specialty network | In-house biomarker and molecular profiling | Patients who haven't had biomarker testing yet | Bangalore |
Apollo Proton Cancer Centre | Private tertiary hospital | JCI-accredited toxicity management infrastructure | Patients considering aggressive combination regimens | Chennai |
Rajiv Gandhi Cancer Institute | Nonprofit tertiary hospital | Structured multidisciplinary tumor board | Patients wanting a second-opinion audit | Delhi |
Sahyadri Hospitals | Private hospital network | Low-dose immunotherapy cost pathway | Budget-conscious patients | Pune |
Cancer Institute (WIA) | Nonprofit charitable hospital | Home-based monitoring between cycles | Patients needing close, low-cost follow-up | Chennai |
7 Cancer Centers in India Offering Combined Chemo-Immunotherapy Access
The seven providers below span a private single-hospital setup, a government trial site, and several large hospital networks, chosen to cover different budgets, biomarker situations, and geographies across India. Each entry explains what the center actually offers and who it fits best.
1. Dr. Bharat Patodiya's Pi Cancer Care, Hyderabad
Pi Cancer Care is a fully equipped cancer treatment hospital in Gachibowli, Hyderabad, founded by medical oncologist Dr. Bharat Patodiya, who trained in medical oncology at Hinduja Hospital, Mumbai, and holds sub-specialty credentials in lung, gastrointestinal, and breast cancer from the University of Zurich and Ulm, Germany. The hospital is built around treating chemotherapy and immunotherapy as one continuous plan rather than separate referrals.
Brings medical oncology, surgical oncology, radiation oncology, and diagnostics under one roof, so patients don't need to travel between facilities for different stages of treatment
In-house diagnostics, including PET-CT and MRI, allow staging and treatment monitoring to happen on-site instead of through outside referrals
Runs an integrative care wing offering genetic counseling, nutritional consultation, and psycho-oncology support alongside active treatment, and according to verified patient reviews, has connected patients who can't afford treatment to charitable funding sources, including the Meera Charitable Trust
Best for: Patients in and around Hyderabad who want one facility covering the full oncology workflow, from diagnostics through immunotherapy-inclusive treatment, under a personally immunotherapy-certified oncologist.
2. Tata Memorial Hospital, Mumbai
Tata Memorial Hospital is India's largest cancer treatment and research center, run under the Department of Atomic Energy and registering well over 100,000 new cancer cases a year across its network. If your priority is a registered, audited trial rather than an off-label arrangement, this is the most direct route.
It anchors one of India's highest volumes of clinical trials, spanning phase I through phase III protocols
It participates in national cooperative group studies, including ALCHEMIST Chemo-IO (protocol A081801), which tests integrating immunotherapy into adjuvant treatment for resected non-small cell lung cancer
Its infrastructure includes round-the-clock lab and critical-care backup, which matters when a trial regimen triggers a sudden immune-related complication
Best for: Patients with a confirmed, staged diagnosis who want access to protocols not offered in the private sector and can work through a formal referral process.
3. HCG Cancer Centre, Bangalore
HCG Cancer Centre starts with molecular profiling before it starts any conversation about immunotherapy. Without knowing your tumor's biomarker status, adding an experimental drug to chemotherapy is closer to guesswork than treatment.
In-house tumor genomics testing flags actionable biomarkers such as dMMR and MSI-H status before a treatment plan is finalized
The center applies findings from major global trials, including the dMMR colon cancer data from Mayo Clinic, to match Indian patients to the protocols shown to work for their specific molecular profile
It sits within HCG's broader national network of more than 20 centers, giving patients a path to second opinions or transfers without starting over elsewhere
Best for: Patients who haven't yet had biomarker testing and want a center that treats it as the starting point, not an afterthought.
4. Apollo Proton Cancer Centre, Chennai
Apollo Proton Cancer Centre is South Asia's first proton therapy center and India's first JCI-accredited cancer hospital. Its real value on this list isn't the proton technology; it's the tertiary-care infrastructure built to catch and treat severe toxicity fast.
JCI accreditation and organ-based Cancer Management Teams that combine surgical, radiation, and medical oncology under a single treatment plan
On-site endocrinology and critical-care backup for the sudden hormonal complications that combination immunotherapy regimens can cause, the kind reported in roughly 1 in 5 patients on dual-checkpoint trials
A high-volume day-care and outpatient setup, supporting over 2,300 OPD visits and 450 chemo day-care sessions monthly
Best for: Patients considering an aggressive combination regimen who want a hospital built to manage toxicity quickly, not just administer the drugs.
5. Rajiv Gandhi Cancer Institute, Delhi
Rajiv Gandhi Cancer Institute and Research Centre runs its cases through a structured, multidisciplinary review rather than a single oncologist's judgment call. For a decision this consequential, a second set of eyes across specialties is worth the extra step.
A standing tumor board spanning medical, surgical, and radiation oncology, pathology, and radiology reviews complex cases before treatment begins
One of Asia's largest dedicated cancer treatment volumes, spread across two Delhi campuses with round-the-clock emergency coverage
A documented, written second-opinion process, useful if you want a formal consensus on file before starting or continuing an experimental protocol
Best for: Patients who already have a treatment plan from another oncologist and want a formal, multidisciplinary review before committing to it.
6. Sahyadri Hospitals, Pune
Sahyadri Hospitals gives budget-conscious patients a real, working path into immunotherapy rather than pricing them out entirely. A 2026 update to an Indian phase 3 trial showed just how far a low-dose approach can stretch.
Oncology infrastructure built around low-dose immunotherapy protocols, the same approach that an updated 2026 trial presented at ASCO showed improved one-year survival from 23% to 46% in advanced head and neck cancer, using a fraction of the standard nivolumab dose
Upfront, itemized cost estimates from a dedicated financial counseling desk, instead of bundled billing that obscures the immunotherapy charge
Part of a nine-hospital Maharashtra network, so oncology, diagnostics, and critical care sit under one group even if you need to move between locations
Best for: Patients weighing the cost of immunotherapy against a fixed budget who want a transparent, itemized estimate before starting. If you may qualify for a government health scheme, ask the hospital's financial counseling team directly about how it applies to your treatment plan before combining it with other funding.
7. Cancer Institute (WIA), Adyar, Chennai
Cancer Institute (WIA) is a nonprofit hospital in Chennai built around treating patients regardless of their ability to pay, and it has quietly built one of India's few formal home-monitoring models for patients on combined protocols.
A community-based, home-monitoring program checks on patients between infusion cycles for early signs of immune-related toxicity, reducing the need for repeated hospital stays
Over seven decades of dedicated cancer care, with a large share of patients treated for free or at heavily subsidized rates
Its own College of Oncological Science trains specialists in medical, surgical, and radiation oncology, reflecting a research and teaching mission alongside direct patient care
Best for: Patients in or near Chennai who need close monitoring between treatment cycles without frequent hospital admissions, particularly those relying on subsidized care.
Conclusion
Start with the biomarker test, not the institution. A dMMR result, an ImPrint score, or HER2/neu overexpression tells you which protocols could plausibly help you, and that answer narrows the seven options above far more than geography does.
Once you have that result, match the institution type to what you actually need next. A confirmed biomarker match with no local access points toward a trial site like Tata Memorial. A still-unclear biomarker picture points toward a profiling-first center like HCG. A regimen with a steep toxicity profile points toward a hospital built for fast intervention, like Apollo Proton. And a tight budget points toward providers who have built low-dose or subsidized pathways, like Sahyadri or Cancer Institute (WIA).
Whichever path you take, get the toxicity monitoring plan in writing before the first infusion, not after the first side effect.
Frequently Asked Questions
What does it mean to combine standard chemotherapy with experimental immunotherapy protocols?
It means receiving cytotoxic drugs that directly kill rapidly dividing cells alongside investigational agents that activate your immune system to attack the tumor. The standard chemotherapy backbone is proven; the immunotherapy is being tested in a clinical trial or registry to determine if the combination improves outcomes above chemotherapy alone.
Which oncologists or cancer centers in India offer combined chemotherapy and experimental immunotherapy?
Several Indian institutions offer this combination in structured settings:
Tata Memorial Hospital: hosts the highest volume of registered trials.
HCG Cancer Centre: uses in-house molecular profiling to match patients to protocols.
Private setups (e.g., Dr. Bharat Patodiya's clinic): coordinate second-opinion access and checkpoint inhibitor delivery.
What are the eligibility criteria for patients wanting to join experimental immunotherapy trials alongside chemotherapy?
Eligibility hinges on biomarker status above all. Key requirements include:
dMMR or MSI-H status for colon cancer.
ImPrint-positive results for breast cancer HER2-negative trials.
HER2/neu overexpression for certain gastric cancer vaccine protocols.
A good ECOG performance score and adequate organ function.
How can a patient find and access clinical trials for immunotherapy in India in 2026?
To find an open protocol, follow these steps:
Search ClinicalTrials.gov with India as the location filter and your cancer type as the condition.
Approach major institutional sites like Tata Memorial Hospital directly.
Contact private coordination services or oncologists embedded in trial networks to identify open chemo-immunotherapy protocol slots.
What are the potential benefits and risks of adding experimental immunotherapy to standard chemotherapy?
Combined chemo-immunotherapy carries both benefits and risks:
Benefits: a potential 50% reduction in recurrence for dMMR colon cancer and doubled one-year survival for certain head and neck cancers.
Primary risk: immune-related toxicity, such as severe endocrine dysfunction affecting the adrenal glands in up to 21% of patients and colitis requiring permanent immunosuppression.
What role do multidisciplinary teams and second opinions play when considering a combined chemo-immunotherapy approach?
They are non-negotiable. A medical oncologist alone cannot fully evaluate the risk-benefit ratio. A tumor board integrates surgery, radiology, endocrinology, and pathology input to confirm the biomarker, rule out contraindications like poor ECOG status, and set a toxicity monitoring plan before the first infusion begins.
Sources
Low Dose of Cancer Immunotherapy Effective in Trial in India - NCI - www.cancer.gov
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with chemotherapy - PMC - pmc.ncbi.nlm.nih.gov
[PDF] NCTN Thoracic Cancer Trials Portfolio (Open as of 5/15/2026) - dctd.cancer.gov
Dual Immunotherapy Trial Results Promising - Georgetown Lombardi - lombardi.georgetown.edu
Immunotherapy boosts chemotherapy in combating stage 3 colon cancer - Mayo Clinic News Network - newsnetwork.mayoclinic.org
Comments